A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning

被引：59

作者：

Knegtering, H. ^{[1
]}

Boks, Marco ^{[1
]}

Blijd, Carl ^{[1
]}

Castelein, Stynke ^{[1
]}

Van den Bosch, Robert J. ^{[1
]}

Wiersma, Durk ^{[1
]}

机构：

[1] Univ Groningen, Med Ctr, Dept Psychiat, NL-9700 RB Groningen, Netherlands

来源：

JOURNAL OF SEX & MARITAL THERAPY | 2006年 / 32卷 / 04期

关键词：

D O I：

10.1080/00926230600666378

中图分类号：

B849 [应用心理学];

学科分类号：

040203 ;

摘要：

The objective of this study was to compare sexual functioning in patients treated with olanzapine or risperidone. This open-label trial included 46 patients randomized to olanzapine (5-15mg/d) or risperidone (1-6mg/d) for 6 weeks. We used sexual dysfunction was assessed by a semistructured interview based on the items of the UKU side effect rating scale. Three olanzapine-treated patients (12.0%), compared with 11 risperidone-treated patients (52.4%), reported sexual dysfunctions (p=.008) in the semistructured interview. Only 4 patients (8.7%) spontaneously reported sexual dysfunction. The mean dose was 9.4 mg/d for olanzapine and 3.4 mg/d for risperidone. The mean (+/- SD) prolactin levels (ng/mL) in olanzapine- and risperidone- reated patients were 25.1 (+/- 23.5) and 43.5 (+/- 26.1), respectively. Less sexual dysfunction occurred in the group treated with olanzapine compared with the risperidone group. Direct questioning about sexual functioning is necessary to avoid underestimating the frequency of sexual side effects in patients with schizophrenia and related psychotic disorders.

引用

页码：315 / 326

页数：12

共 63 条

[1]

AIZENBERG D, 1995, J CLIN PSYCHIAT, V56, P137

[2] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].

Beasley, CM ;

Tollefson, G ;

Tran, P ;

Satterlee, W ;

Sanger, T ;

Hamilton, S ;

Fabre, L ;

Small, J ;

Ereshefsky, L ;

True, J ;

Nemeroff, C ;

Risch, SC ;

Perry, PJ ;

Potkin, SG ;

Borison, RL ;

James, S ;

Meltzer, HY ;

Iqbal, N ;

Fann, WE ;

Gewirtz, GR ;

Landbloom, R ;

RoyByrne, PP ;

Tuason, VB ;

Carman, JS ;

Stokes, PE ;

Williams, R ;

Ancill, RJ ;

MacEwan, GW ;

Gujavarty, KS ;

Jones, B ;

Lohr, JB .

NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123

[3] ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia [J].

Borison, RL ;

Arvanitis, LA ;

Miller, BG ;

Alphs, LD ;

Carman, JS ;

Diamond, B ;

Gewirtz, G ;

Hamner, MB ;

Hirshfield, R ;

McEvoy, JP ;

Mukherjee, S ;

Nasrallah, HA ;

Oxenkrug, G ;

Ryan, W ;

Smith, N ;

Tamminga, C .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (02) :158-169

[4]

BURSATTO GF, 1993, BRIT J PSYCHIAT, V163, P833

[5]

BURSATTO GF, 1995, PSYCHOPHARMACOLOGY, V117, P55

[6] Olanzapine use in women with antipsychotic-induced hyperprolactinemia [J].

Canuso, CM ;

Hanau, M ;

Jhamb, KK ;

Green, AI .

AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (10) :1458-1458

[7] Prolactin and testosterone: Their role in male sexual function [J].

Carani, C ;

Granata, ARM ;

Fustini, MF ;

Marrama, P .

INTERNATIONAL JOURNAL OF ANDROLOGY, 1996, 19 (01) :48-54

[8] Hyperprolactinaemia induced by risperidone [J].

Chung, YC ;

Eun, HB .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 1998, 1 (01) :93-94

[9] RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC INPATIENTS - A MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY [J].

CLAUS, A ;

BOLLEN, J ;

DECUYPER, H ;

ENEMAN, M ;

MALFROID, M ;

PEUSKENS, J ;

HEYLEN, S .

ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) :295-305

[10] The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations [J].

Crawford, AMK ;

Beasley, CM ;

Tollefson, GD .

SCHIZOPHRENIA RESEARCH, 1997, 26 (01) :41-54

← 1 2 3 4 5 6 7 →